Period Pills by Biikay (Acetaminophen, Ibuprofen)
Brand Names: Period Pills by Biikay
Methodology & AI Transparency ⓘ
Period Pills by Biikay (Acetaminophen, Ibuprofen) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within the Nonsteroidal Anti-inflammatory Drug category, Period Pills by Biikay provides branded delivery of active moiety Acetaminophen, Ibuprofen (cross-referenced at /meds/acetaminophen-ibuprofen) (registered by Kai Squared; NDC 85576-101).
- 2 Real-world patient consensus: Registered under RxNorm 2387532-B85576101 and SPL 2026-06-01, pairing Period Pills by Biikay packaging with active ingredient Acetaminophen, Ibuprofen.
- 3 Typical cash cost range: 30-day cash pricing ranges from $15.16 discount cash to $40.17 walk-in retail (NADAC $0.0925/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Period Pills by Biikay (Acetaminophen, Ibuprofen): headache (11.4%), nausea (7.4%), dizziness (6.4%).
Ask our AI Specialists anything about Period Pills by Biikay (Acetaminophen, Ibuprofen)
Period Pills by Biikay (Acetaminophen, Ibuprofen) Mechanism, CYP450 Pathways & DailyMed Monograph
Within the Nonsteroidal Anti-inflammatory Drug category, Period Pills by Biikay provides branded delivery of active moiety Acetaminophen, Ibuprofen (cross-referenced at /meds/acetaminophen-ibuprofen) (registered by Kai Squared; NDC 85576-101). Characterized by 250 mg/1 / 125 mg/1 Tablet; Longitudinal Period Pills by Biikay (Acetaminophen, Ibuprofen) dosing interval tailored to tolerability under 2026-06-01 SPL documentation, Period Pills by Biikay targets USES(S) Temporarily relieves minor aches and pains due to: headache, toothache, backache, menstrual cramps, muscular.
Through its Acetaminophen, Ibuprofen active moiety, Period Pills by Biikay exerts nonsteroidal anti-inflammatory drug activity with class-characteristic hepatorenal disposition. Registered under NDC 85576-101 (registered by Kai Squared; effective 2026-06-01), the 250 mg/1 / 125 mg/1 Tablet; Longitudinal Period Pills by Biikay (Acetaminophen, Ibuprofen) dosing interval tailored to tolerability presentation ensures reproducible pharmacokinetic release profiles documented in federal RxNorm (2387532-B85576101) and CMS NADAC ($0.0925/unit) ledgers.
Systemic exposure to Period Pills by Biikay (Acetaminophen, Ibuprofen) reflects Systemic oral bioavailability of roughly 70%–82% following first-pass transit absorption kinetics and hepatic enzymatic processing and renal clearance proportional to creatinine clearance (period pills by biikay (acetaminophen, ibuprofen)), sustaining receptor engagement across a Biphasic clearance with 5–13 hr terminal t½ under Period Pills by Biikay (Acetaminophen, Ibuprofen) maintenance half-life window (initial pharmacodynamic onset within 1–3 hrs (peak cmax) for period pills by biikay (acetaminophen, ibuprofen) response profile).
Dosing protocols (250 mg/1 / 125 mg/1 Tablet or Longitudinal Period Pills by Biikay (Acetaminophen, Ibuprofen) dosing interval tailored to tolerability) balance efficacy (85.00% patient satisfaction across 18 logs) against headache (11.4% of reports), nausea (7.4% of reports), dizziness (6.4% of reports), with strict avoidance in severe drug-induced hypersensitivity to acetaminophen, ibuprofen or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-06-01 for period pills by biikay (acetaminophen, ibuprofen).
Assess baseline hepatic panels and interacting prescriptions when starting Period Pills by Biikay (Acetaminophen, Ibuprofen) (nonsteroidal anti-inflammatory drug).
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Period Pills by Biikay (Acetaminophen, Ibuprofen) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Acetaminophen, Ibuprofen or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-06-01 for Period Pills by Biikay (Acetaminophen, Ibuprofen)
Logged Side-Effect Incidence (18 Reports)
Period Pills by Biikay (Acetaminophen, Ibuprofen) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Period Pills by Biikay (Acetaminophen, Ibuprofen))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of adjunctive local periodontal treatment for type 2 diabetes patients: What a 1,224-Participant Study Found This study moderately supports that adding metformin or statins locally to NSPT may enhance PD reduction and CAL gain compared to SRP with/without placebo. Journal of dentistry • 2024-09-15 • Meta-Analysis | N = 1,224 | 99/100 | PMID 38936456 ↗ |
| New Insights on A meta-analysis on the association between obstructive sleep apnea and: What a 31,800-Participant Study Found The findings suggest that OSA was associated with an increased prevalence of periodontitis. Sleep & breathing = Schlaf & Atmung • 2023-05-15 • Meta-Analysis | N = 31,800 | 94/100 | PMID 35759182 ↗ |
| New Insights on Selected side effects during the 12-week induction period of a phase III trial of: What a 690-Participant Study Found Vunakizumab is not significantly associated with the occurrence of any AE or most selected AE categories in patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups, whereas vunakizumab is associated... Frontiers in immunology • 2026-01-15 • Phase III Randomized Trial | N = 690 | 93/100 | PMID 42952621 ↗ |
| New Insights on A phase 3, randomized, gold-standard blind, active-controlled clinical study to: What a 528-Participant Study Found Outcomes were comparable among the groups in TP2, with no impact from the UST-to-BAT2206 switch. Journal of the American Academy of Dermatology • 2025-12-15 • Phase III Randomized Trial | N = 528 | 93/100 | PMID 40784561 ↗ |
| Can This Approach Help? Inside the Latest Research on One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in One year of exercise increased late-phase postprandial GLP-1 response, which may prevent increased appetite after weight loss and thereby weight regain. Obesity (Silver Spring, Md.) • 2026-01-15 • Randomized Controlled Trial | N = 195 | 88/100 | PMID 40998556 ↗ |
Period Pills by Biikay (Acetaminophen, Ibuprofen) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0925/unit (~$2.77/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $40.17 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $15.16 / mo | View logs ↓ |
Period Pills by Biikay (Acetaminophen, Ibuprofen) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Period Pills by Biikay (Acetaminophen, Ibuprofen) RxNorm Concept ID | 2387532-B85576101 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0925 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $40.17 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $15.16 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 85.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Period Pills by Biikay (Acetaminophen, Ibuprofen) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Period Pills by Biikay (Acetaminophen, Ibuprofen) integrating DailyMed SPL (2026-06-01), CMS NADAC ($0.0925/unit), and 18 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Period Pills by Biikay (Acetaminophen, Ibuprofen) community threads and patient logs by age, biological sex, dosage, and treatment duration.